1. Home
  2. PYN vs UBX Comparison

PYN vs UBX Comparison

Compare PYN & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PYN
  • UBX
  • Stock Information
  • Founded
  • PYN 2002
  • UBX 2009
  • Country
  • PYN United States
  • UBX United States
  • Employees
  • PYN N/A
  • UBX N/A
  • Industry
  • PYN Investment Managers
  • UBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PYN Finance
  • UBX Health Care
  • Exchange
  • PYN Nasdaq
  • UBX Nasdaq
  • Market Cap
  • PYN 33.5M
  • UBX 38.6M
  • IPO Year
  • PYN N/A
  • UBX 2018
  • Fundamental
  • Price
  • PYN $5.78
  • UBX $1.98
  • Analyst Decision
  • PYN
  • UBX Strong Buy
  • Analyst Count
  • PYN 0
  • UBX 2
  • Target Price
  • PYN N/A
  • UBX $7.00
  • AVG Volume (30 Days)
  • PYN 19.9K
  • UBX 335.8K
  • Earning Date
  • PYN 01-01-0001
  • UBX 11-04-2024
  • Dividend Yield
  • PYN 5.07%
  • UBX N/A
  • EPS Growth
  • PYN N/A
  • UBX N/A
  • EPS
  • PYN N/A
  • UBX N/A
  • Revenue
  • PYN N/A
  • UBX N/A
  • Revenue This Year
  • PYN N/A
  • UBX N/A
  • Revenue Next Year
  • PYN N/A
  • UBX $33.62
  • P/E Ratio
  • PYN N/A
  • UBX N/A
  • Revenue Growth
  • PYN N/A
  • UBX N/A
  • 52 Week Low
  • PYN $4.84
  • UBX $0.94
  • 52 Week High
  • PYN $6.60
  • UBX $3.10
  • Technical
  • Relative Strength Index (RSI)
  • PYN 49.82
  • UBX 51.50
  • Support Level
  • PYN $5.68
  • UBX $1.81
  • Resistance Level
  • PYN $5.89
  • UBX $2.39
  • Average True Range (ATR)
  • PYN 0.05
  • UBX 0.24
  • MACD
  • PYN 0.01
  • UBX -0.06
  • Stochastic Oscillator
  • PYN 47.19
  • UBX 26.56

About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest

PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Share on Social Networks: